Fennec Pharmaceuticals Inc. (FENC) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals strong financial performance, with a 73% increase in net product sales and positive cash flow. The strategic global expansion and clinical initiatives, coupled with market exclusivity until 2033, further strengthen the outlook. Despite minor concerns about milestone payment uncertainties and operational ramp-up, the positive sentiment is bolstered by optimistic guidance, robust shareholder return plans, and the potential for label expansion through ISTs. The Q&A session supports this sentiment, highlighting growth in demand and strategic targeting of high-volume prescribers.
Key Financial Performance
Net Product Sales $15.1 million for Q1 2026, a 73% increase year-over-year compared to $8.8 million in Q1 2025. The increase is attributed to continued momentum in delivering PEDMARK to patients, record new patient enrollments, and strong commercial execution.
Operating Expenses (OpEx) Approximately $14 million for Q1 2026, a year-over-year increase of $6 million. The increase is due to expanded marketing investment and increased commercial headcount to support PEDMARK growth.
Cash and Cash Equivalents $40.1 million as of March 31, 2026, with a net increase of $3.3 million during the quarter. The increase consisted of $2.3 million in operating cash flow and $1 million from option exercises.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
PEDMARK clinical interest: Growing clinical interest in PEDMARK, with three new investigator-initiated studies announced to evaluate its use in adolescent and young adults (AYA) and adult patients with head and neck and testicular cancers receiving cisplatin.
PEDMARK approvals and recommendations: PEDMARK is approved for pediatric patients with localized non-metastatic solid tumors and has a 2A recommendation for use in AYA patients by the National Comprehensive Cancer Network.
Market expansion in Japan: Positive informal PMDA meeting in Japan and ongoing exploration of partnering opportunities in the region.
Territorial expansion: Investment in 14 new territories and 4 frontline managers to expand healthcare professional engagement and adoption of PEDMARK.
Project Ignite: Launched in late Q4 2025 to optimize reach and frequency, resulting in increased prescriber target base from 1,300 to over 5,000.
Fennec HEARS program: Full-service patient support program showing a 48% quarter-over-quarter increase in completed infusions and achieving an 80% conversion rate for the first time.
Cross-functional collaboration: Durable growth achieved through persistent engagement across medical, sales, market access, and patient support services.
Market access initiatives: Partnership with a fast-growing oncology aggregator to integrate PEDMARK into their network, supporting top-down adoption.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company is in ongoing conversations and exploring partnering opportunities in Japan, which may involve regulatory hurdles and uncertainties.
Market Sensitivity: The AYA market is described as promotionally sensitive, requiring effective communication and engagement to drive adoption, which could pose challenges in maintaining momentum.
Operational Ramp-Up: The expansion of the sales force and onboarding of new talent involves a natural ramp period, which could delay immediate impact on commercial performance.
Financial Risks: The company anticipates select quarterly swings in cash position due to collection cycles with customers, which could impact financial stability in the short term.
Milestone Payment Uncertainty: The company does not anticipate receiving the German milestone payment from its partner, Norgine, which could affect expected revenue streams.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company anticipates sustained revenue growth throughout 2026, with Q2 demand tracking to surpass Q1. April 2026 demand through Fennec HEARS alone accounted for more than 50% of the total Q1 demand.
Market Expansion: The company expanded its sales territories and frontline managers in Q1 2026, increasing its prescriber target base from 1,300 to over 5,000. This expansion is expected to drive greater impact through increased reach, frequency, and account penetration.
Clinical Studies and Adoption: Fennec is encouraged by growing clinical interest in PEDMARK, with three new investigator-initiated studies and four abstracts accepted for presentation at the ASCO Annual Meeting. These efforts aim to support broader clinical adoption and expand PEDMARK's use in new patient populations and tumor types.
Japan Market Opportunities: The company had a positive informal PMDA meeting earlier in 2026 and is exploring partnering opportunities in Japan.
Operational Metrics: The company reported a 48% quarter-over-quarter increase in completed infusions through Fennec HEARS and achieved an 80% conversion rate for patients progressing to therapy. Adherence trends remain strong at approximately 80%.
Financial Outlook: Fennec expects approximately $50 million in cash operating expenses for 2026, with over 60% of these expenses occurring in the first half of the year. The company anticipates positive cash flow growth in the second half of 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What drove the upside in KPIs and performance in Q1?
A:The upside was driven by the expansion of reach and frequency through Project Ignite, significant uptake in April, and growth in demand for Fennec HEARS. Growth was balanced between academic and community settings, with increased reach and frequency contributing to growth in both AYA and pediatric segments.
Q:Why did the company decide to go with the ISTs and tumor types they did?
A:The ISTs were chosen to establish the company's position in the space and generate data in populations like AYA adult testicular. This data helps address physician pushback and expands awareness of PEDMARK. The ISTs also lead to increased commercial use within institutions as more physicians, pharmacists, and nurses become familiar with the product.
Q:What percentage of volume or demand was driven by new rep hires, and how is their productivity trending in Q2?
A:New territories contributed significantly to new prescriptions and patients. The hiring and training of new sales reps began in Q4 and Q1, with productivity ramping up in March. Early signs indicate a good balance between new and existing accounts, with continued adoption expected in the second half of the year.
Q:What is the stability of pediatric revenue, and what percentage of business is flowing through Fennec HEARS?
A:Pediatric revenue is growing but at a slower pace than AYA. About 50% of the business and demand in April came through Fennec HEARS, with this percentage increasing as implementation improves and more patients are added.
Q:What is the company's approach to life cycle management for PEDMARK, and is there an appetite for acquiring another asset?
A:The company is focusing on life cycle management by expanding into new populations and tumor types, such as metastatic and adult patients. They are also open to acquiring additional products to leverage their expanded commercial team and resources.
Q:What is the typical profile of a high-volume prescriber for PEDMARK, and how many such physicians are there in the U.S.?
A:High-volume prescribers are found in both academic and community settings. The company is targeting about 5,400 physicians, up from just over 1,000 previously, with a balanced approach to engaging both academic centers and community practices.
Q:How many additional investigator-initiated trials (ISTs) are expected this year, and could they lead to label expansion?
A:The company expects more ISTs but did not specify a number. These trials are strategically chosen and could lead to regulatory conversations and label expansion as data matures.
Q:What is the internal pipeline for targeting new patient populations treated with platinum-based chemotherapies?
A:The company is targeting tumor types where cisplatin is commonly used, such as testicular, head and neck, cervical, bladder, and lung cancers. These areas represent significant opportunities for PEDMARK.
Q:How is the PEDMARQSI launch progressing, and when will it impact revenues?
A:PEDMARQSI is being launched in multiple markets in 2026, with significant growth expected this year. Royalties start in the mid-teens, and milestones tied to sales will contribute to revenue growth.
Q:Review of Unclear Management Responses
A:Management avoided providing specific numbers or timelines for the expected number of ISTs this year and the exact impact of PEDMARQSI on revenues. Additionally, while they mentioned being open to acquiring new assets, no concrete plans or details were shared.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ASCO
AYA adult
CIO
Cancer
KOL
National
PEDMARK patient
access support
approach
care patient
collaboration
conversion rate
demand therapy
footprint
force
head neck
home infusion
indicator
investment
manager
market access
member
mix
model
neck cancer
order set
patient provider
prescription demand
reach frequency
record
sale market
service
site
standard
study
tumor type
utilization
FENC Transcript
Fennec Pharmaceuticals Inc. (FENC) Q1 2026 Earnings Call Transcript
Positive5-14
The earnings call reveals strong financial performance, with a 73% increase in net product sales and positive cash flow. The strategic global expansion and clinical initiatives, coupled with market exclusivity until 2033, further strengthen the outlook. Despite minor concerns about milestone payment uncertainties and operational ramp-up, the positive sentiment is bolstered by optimistic guidance, robust shareholder return plans, and the potential for label expansion through ISTs. The Q&A session supports this sentiment, highlighting growth in demand and strategic targeting of high-volume prescribers.
Fennec Pharmaceuticals Inc. (FENC) Q4 2025 Earnings Call Transcript
Positive3-24
The earnings call summary and Q&A section reveal a positive sentiment. Key highlights include the successful launch of PEDMARK in Europe and the U.K., significant expansion plans, and strong growth trends in the AYA patient segment. The field force expansion and the Fennec HEARS program are expected to drive sales growth. While financial guidance is pending, the anticipated revenue from partnerships and the resolution of litigation issues further bolster the outlook. The absence of unclear management responses also supports a positive sentiment.
Fennec Pharmaceuticals Inc. (FENC) Q2 2025 Earnings Call Transcript
Positive8-19
The earnings call highlights strong financial performance with an 18% sales growth, expansion into new markets, and optimistic future revenue expectations. The Q&A session reveals positive growth in new and repeat customers and strategic market expansion, particularly in the AYA segment, despite some reluctance to share specific numbers. The company's strategy to enhance programs and expand in Europe and Japan indicates a proactive approach, supporting a positive sentiment. However, the lack of specific guidance and royalty impact tempers the outlook slightly, leading to a positive rather than strong positive rating.
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q1 2025 Earnings Call Transcript
Unknown5-14
The earnings call presents mixed signals. Financial performance shows growth, but cash burn and competitive pressures are concerns. The international launch and market expansion are positive, but regulatory and supply chain risks loom. The Q&A reveals some management opacity, particularly around breakeven figures. Without a share repurchase plan and given the lack of strong guidance, the sentiment leans neutral. The absence of market cap data limits the assessment of stock price sensitivity.
FENC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
